Adiponectin receptor (AdipoR1 and AdipoR2) modulators represent a promising class of neuroprotective therapies that bridge metabolic health and brain function. Adiponectin — the most abundant adipokine in circulation — exerts anti-inflammatory, metabolic, neurotrophic, and neuroprotective effects through these receptors. Dysregulation of adiponectin signaling is implicated in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease, making AdipoR modulation a cross-disease therapeutic strategy[1].
The adiponectin system is uniquely positioned as a therapeutic target because it addresses multiple convergent pathways in neurodegeneration: metabolic dysfunction, chronic neuroinflammation, impaired autophagy, mitochondrial failure, and synaptic dysfunction. Unlike single-target approaches that have largely failed in clinical trials, adiponectin agonism simultaneously engages the AMPK, PPAR-alpha, and SIRT1 axes — all of which are dysregulated in neurodegenerative diseases.
Adiponectin signals through two receptor subtypes with distinct expression patterns and signaling profiles:
AdipoR1 is widely expressed in brain tissue, skeletal muscle, and heart. It has high affinity for high-molecular-weight (HMW) and medium-molecular-weight (MMW) adiponectin isoforms, and primarily activates the AMPK pathway. AdipoR1 is the dominant receptor in neurons and glia.
AdipoR2 is expressed in liver and brain with intermediate affinity for all isoforms. It primarily activates the PPAR-alpha pathway and provides secondary AMPK activation.
Both receptors are G-protein-independent, working through adaptor protein (APPL1) engagement to activate downstream kinases. Reduced expression of both receptors has been documented in Alzheimer's disease patient brains[2].
| Mechanism | Adiponectin Effect | Disease Relevance |
|---|---|---|
| AMPK activation | Restores autophagy, inhibits mTOR | AD (A-beta/tau clearance), PD (alpha-syn clearance) |
| Neuroinflammation | Promotes M2 microglial polarization, inhibits NF-kB | All neurodegenerative diseases |
| Mitochondrial function | Enhances biogenesis, reduces ROS | PD (dopaminergic neurons), AD, ALS |
| Synaptic plasticity | Enhances LTP, dendritic spine density | AD (cognitive decline), HD |
| Cerebral blood flow | Improves microcirculation | Vascular dementia, AD |
| Neurogenesis | Promotes hippocampal progenitor proliferation | AD, cognitive aging |
| Amyloid clearance | Enhances BBB transport, microglial phagocytosis | AD |
| Alpha-synuclein | Protects against aggregation and toxicity | PD, DLB |
AdipoRon is the most advanced adiponectin receptor agonist in development, activating both AdipoR1 and AdipoR2 with comparable potency. It was originally developed for metabolic disease (type 2 diabetes) and has since shown robust neuroprotective effects in multiple preclinical models[3].
Mechanism of action:
Preclinical evidence:
| Model | Effect | Reference |
|---|---|---|
| 5xFAD AD mice | Reduced amyloid plaque load, improved cognition | [3:1] |
| MPTP PD mice | Protected dopaminergic neurons, improved motor function | [4] |
| EAE model (MS) | Ameliorated neuroinflammation, reduced demyelination | [5] |
| APP/PS1 AD mice | Improved cerebral blood flow, synaptic density | [6] |
| SOD1 ALS mice | Delayed disease onset, extended survival | [7] |
Clinical status:
Formulation challenges:
Osmotin is a plant pathogenesis-related (PR) protein that acts as a functional adiponectin receptor agonist. It has been detected in yeast and plant extracts and shown to activate AdipoR1/R2 signaling[8].
Mechanism: Osmotin binds AdipoR1 and AdipoR2, activating the AMPK pathway and producing anti-inflammatory effects similar to adiponectin. It shares the APPL1-dependent signaling mechanism.
Preclinical findings:
Limitations: Limited bioavailability, need for structural optimization for mammalian systems, no human data.
Full-length high-molecular-weight (HMW) adiponectin is the most biologically active isoform and has shown superior neuroprotective effects compared to other isoforms.
Formulation considerations:
Preclinical data: Enhanced BBB penetration demonstrated in rodent models; neuroprotection in AD and PD models. No human trials yet.
Several strategies enhance adiponectin receptor function without direct agonism:
Exercise — The most effective physiological approach[9]:
AMPK activators — Agents that activate AMPK downstream of the receptor:
PPAR-alpha agonists — Fibrates and related compounds:
SIRT1 activators:
Emerging targets upstream of AdipoR signaling:
NAT10 N4-acetylcytidine modification — A 2025 study showed that NAT10 (N-acetyltransferase 10) induces mRNA modification of AdipoR1, enhancing translation efficiency and mitochondrial function in neuronal cells. NAT10 represents an upstream target to enhance AdipoR1 expression and function[10].
Monocarboxylate transporter (MCT) enhancement — Adiponectin receptor agonism strengthens brain energy transport through MCTs, addressing the hypometabolism characteristic of AD brains[11]. This suggests combination approaches targeting both receptor signaling and brain energy substrate delivery.
| Agent | Company / Institution | Phase | Indication | Status |
|---|---|---|---|---|
| AdipoRon | Dainippon Sumitomo / Keio University | Phase I (metabolic) | T2DM — completed | No neurodegenerative trials yet |
| Exercise intervention | Multiple academic centers | Phase II | AD, PD | Recruiting |
| Omega-3 + exercise | Academic | Phase II | MCI | Completed (positive) |
| Metformin | Multiple | Phase III | AD prevention | Ongoing |
| Berberine | Academic | Phase II | PD | Recruiting |
| Biomarker | Sample | Utility |
|---|---|---|
| Serum total adiponectin | Blood (fasting) | Predicts AD progression — reduced 20-40% in AD/PD patients |
| HMW adiponectin ratio | Blood | Ratio <0.4 associated with 2x faster cognitive decline |
| CSF adiponectin | Cerebrospinal fluid | Reduced 25% in AD/PD; inversely correlates with tau/alpha-syn[12] |
| AdipoR1/R2 expression | Peripheral blood cells | Downregulated in AD/PD; surrogate for CNS receptor status |
| Phospho-AMPK | Peripheral cells | Direct marker of pathway activation |
| Adiponectin-to-leptin ratio | Blood | Low ratio (<1) associated with increased neurodegeneration risk |
Adiponectin modulation addresses multiple AD pathological hallmarks:
Clinical data: Serum adiponectin is reduced in AD patients, and lower levels correlate with faster cognitive decline and higher CSF tau[14].
Adiponectin is neuroprotective in PD models through:
Adiponectin levels correlate with ALS disease progression[7:1]:
The metabolic dysfunction characteristic of HD makes adiponectin targeting relevant:
Metabolic dysfunction is a convergent feature across AD, PD, ALS, and HD:
Adiponectin — as the adipokine most strongly linked to insulin sensitivity and metabolic health — is therefore a compelling cross-disease target. AdipoR agonism addresses the metabolic component shared across these diseases while also providing neuroprotective effects independent of metabolic status.
Near-term (exercise-based approaches):
Medium-term (repurposing approaches):
Long-term (direct AdipoR agonists):
Adiponectin-based therapies may be most beneficial for:
Caution in advanced disease where compensatory adiponectin elevation may already be maximal.
Ng RC, et al. Adiponectin in the brain and neurodegenerative diseases. Exp Neurol. 2020. ↩︎
Park J, et al. Adiponectin receptor expression in human Alzheimer disease brain. Acta Neuropathol. 2023. ↩︎
Qin L, et al. Adiponectin receptor agonist AdipoRon in neurodegenerative disease models. Mol Neurobiol. 2023. ↩︎ ↩︎
Xia Y, et al. Adiponectin ameliorates mitochondrial dysfunction in Parkinson disease models. Neurobiol Dis. 2024. ↩︎ ↩︎ ↩︎
Wang Q, et al. AdipoRon ameliorates neuroinflammation in EAE models. J Neuroimmunol. 2024. ↩︎
Chen X, et al. Adiponectin improves cerebral blood flow in Alzheimer disease models. Neurobiol Aging. 2023. ↩︎ ↩︎ ↩︎
Zhao M, et al. Adiponectin in ALS: biomarker and therapeutic potential. Neurobiol Dis. 2024. ↩︎ ↩︎
Islam A, et al. Osmotin abrogates abnormal metabolic-associated neurodegeneration. Mol Neurobiol. 2024. ↩︎ ↩︎
Chen B, et al. Exercise and adiponectin in brain health. Exp Gerontol. 2024. ↩︎
Chen W, et al. NAT10 induces N4-acetylcytidine modification of AdipoR1-mediated mitochondrial function. Nat Commun. 2025. ↩︎
Liu S, et al. Strengthening monocarboxylate transporters by adiponectin receptor agonism. Cell Metab. 2025. ↩︎
Lee K, et al. Cerebrospinal fluid adiponectin in neurodegenerative diseases. Ann Neurol. 2023. ↩︎
Jiang Y, et al. Adiponectin attenuates neuroinflammation and synaptic dysfunction in AD. Exp Neurol. 2022. ↩︎ ↩︎
Zhou P, et al. Adiponectin and insulin resistance in Alzheimer disease. Metabolism. 2022. ↩︎
Tan J, et al. Adiponectin protects against alpha-synuclein toxicity. Mov Disord. 2024. ↩︎